ZEVRA THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $623.18M
- P/E (TTM)
- 10.9
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $39.70M | $0.14 | $0.25 |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $36.20M | $0.60 | $0.18 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | After market close | $34.10M | $0.19 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | $26.10M | $-0.01 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | $25.90M | $1.21 | $-0.06 |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $20.40M | $-0.06 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | After market close | $12.00M | $-0.67 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $3.70M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
Press releases
Announcements Zevra Therapeutics filed with the SEC
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Material agreement · Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
Results of operations · Executive or director change · EX-99.2 to Form 8-K
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Zevra Therapeutics, Inc. Announces CFO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Zevra Reports First Quarter 2025 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Acquisition or disposition completed · Results of operations · Other events · EX-99.1 to Form 8-K
Zevra Reports Fourth Quarter and Full Year 2024
Results of operations · EX-99.1 to Form 8-K
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Zevra Therapeutics Announces Organizational Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA ™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zevra Therapeutics Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zevra Therapeutics ’ MIPLYFFA ™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
FDA Advisory Committee Votes Favorably that the Data Support
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
Regulation FD disclosure · EX-99.1 to Form 8-K
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
Regulation FD disclosure · EX-99.1 to Form 8-K
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
This Securities Purchase Agreement (this Agreement ) is dated as of November 20, 2023, between Zevra Therapeutics,
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
THE SPECIAL MEETING OF STOCKHOLDERS
Other events · EX-99.1 to Form 8-K
Filed by Zevra Therapeutics, Inc.
Other events · EX-99.1 to Form 8-K
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Acquisition August 31, 2023 Exhibit 99.2
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · EX-99.2 to Form 8-K
Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Executive or director change · EX-99.2 to Form 8-K